We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-1.29%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.33B
AUM Growth
+$549M
(+31%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
5.6%
Top 10 Holdings %
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Weyerhaeuser
WY
|
+$59M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$33.1M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$9.18M |
| 4 |
AGN
Allergan plc
AGN
|
+$6.91M |
| 5 |
CNSY
Cerenome
CNSY
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$12.1M |
| 2 |
BPTH
Bio-Path Holdings Inc
BPTH
|
+$8.78M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$7.12M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$6.23M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$4.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 86.57% |
| 2 | Healthcare | 9.72% |
| 3 | Real Estate | 2.82% |
| 4 | Energy | 0.36% |
| 5 | Consumer Discretionary | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
CALL
Gilead Sciences
GILD
$181B
| $16.6M | 0.71% |
3,006
+13
| +0.4% | +$1.01K |
|
27
PUT
AbbVie
ABBV
$465B
| $15.3M | 0.66% |
2,712
-267
| -9% | -$14K |
|
|
SGMO
28
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $15.3M | 0.66% |
10,012
+2
| +0% | +$29 |
|
29
PUT
Biogen
BIIB
$31.9B
| $15M | 0.64% |
477
+427
| +854% | +$129K |
|
|
GEVA
30
PUT
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $13.9M | 0.6% |
1,331
| – | – |
|
|
31
Regeneron Pharmaceuticals
REGN
$79.7B
| $13.6M | 0.58% |
48,177
+30,986
| +180% | +$9.18M |
|
32
Acadia Pharmaceuticals
ACAD
$4.61B
| $13.3M | 0.57% |
589,264
+126,118
| +27% | +$2.63M |
|
33
PUT
Amgen
AMGN
$203B
| $13.2M | 0.56% |
1,113
-25
| -2% | -$2.89K |
|
|
TPH
34
PUT
DELISTED
Tri Pointe Homes
TPH
| $12.4M | 0.53% |
+7,886
| New | +$127K |
|
|
ACHN
35
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
| $12.1M | 0.52% |
15,987
+1,294
| +9% | +$5.16K |
|
36
Tenax Therapeutics
TENX
$68.5M
| $11.1M | 0.48% |
85
+19
| +29% | +$2.93M |
|
37
Opko Health
OPK
$1.17B
| $10.6M | 0.45% |
1,193,955
+362,718
| +44% | +$3.17M |
|
38
PUT
Outfront Media
OUT
$4.95B
| $9.32M | 0.4% |
+2,004
| New | +$47.2K |
|
39
PUT
Bristol-Myers Squibb
BMY
$130B
| $9.19M | 0.39% |
1,894
+1,722
| +1,001% | +$84.9K |
|
|
AEGR
40
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
| $8.66M | 0.37% |
+2,700
| New | +$101K |
|
41
CALL
AstraZeneca
AZN
$251B
| $8.56M | 0.37% |
+1,152
| New | +$83.3K |
|
|
IOC
42
DELISTED
Interoil Corporation
IOC
| $8.43M | 0.36% |
131,794
+89,433
| +211% | +$5.71M |
|
|
CLVS
43
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $8.27M | 0.35% |
1,998
+67
| +3% | +$3.45K |
|
|
AUXL
44
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $7.7M | 0.33% |
3,839
-144
| -4% | -$3.3K |
|
|
AGN
45
DELISTED
Allergan plc
AGN
| $7.45M | 0.32% |
+33,376
| New | +$6.91M |
|
|
46
PUT
AstraZeneca
AZN
$251B
| $7.37M | 0.32% |
+992
| New | +$71.7K |
|
47
CALL
Alkermes
ALKS
$7.72B
| $7.05M | 0.3% |
1,401
+1,228
| +710% | +$56.6K |
|
|
CDMO
48
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $7.03M | 0.3% |
41,657
+7,599
| +22% | +$95.8K |
|
|
49
CALL
Bristol-Myers Squibb
BMY
$130B
| $6.85M | 0.29% |
1,413
-15,258
| -92% | -$752K |
|
50
PUT
Alnylam Pharmaceuticals
ALNY
$31.9B
| $6.8M | 0.29% |
+1,076
| New | +$64K |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q2 2014 Portfolio in Review
As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Sabby Management deployed $131M of net new capital in Q2 2014, opening 83 new positions and adding to 72 existing holdings. Its largest new stake was Weyerhaeuser: 1,950,977 shares worth $64.6M.
By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 89% a quarter earlier, followed by Healthcare and Real Estate.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $7.12M trimmed.
- Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
- Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
- Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
- Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
- Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
- Sabby Management opened 83 new positions and closed 65 in Q2 2014.
- Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.
Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.